Ozanimod-Relapsing Forms of Multiple Sclerosis

Introduction

An immunomodulatory drug called Ozanimod is used to treat relapse forms of multiple sclerosis (MS). Ozanimod, a member of the sphingosine-1-phosphate (S1P) receptor modulator class, reduces inflammation and autoimmune responses by modifying the immune system. It inhibits some immune cells from migrating into the central nervous system by attaching to S1P receptors on immune cells. This lowers the frequency of relapses, slows the course of disability, and reduces the number of new brain lesions in MS patients. The Food and Drug Administration approved Ozanimod on the 26th of March, 2020.

Indications of Ozanimod:

The main purpose of Ozanimod is to treat relapse types of multiple sclerosis (MS). Among these signs are:

• Relapsing-Remitting Multiple Sclerosis (RRMS): Patients with RRMS, which is typified by flare-ups (relapses) of symptoms interspersed with remissions, are treated with Ozanimod.

• Active Secondary Progressive Multiple Sclerosis (SPMS): In patients with active secondary progressive multiple sclerosis (SPMS), where relapses and disease activity are still evident, Ozanimod is also recommended.

Contraindications of Ozanimod:

Ozanimod has several contraindications, which means that using it in specific circumstances or medical conditions is not advised because of possible dangers or adverse effects. Ozanimod contraindications consist of:

• Hypersensitivity: The drug should not be used by anyone with a history of recognized hypersensitivity or allergic reaction to Ozanimod or its ingredients.

• Recent Myocardial Infarction (Heart Attack): As Ozanimod may raise the risk of cardiovascular complications, it should not be used by anyone who has recently had a heart attack (myocardial infarction), unstable angina (chest discomfort or pain caused by insufficient blood flow), stroke (reduction or interruption in blood supply to a part of the brain), transient ischemic attack (TIA) (temporary disruption of blood supply to a part of the brain), or other major cardiovascular events.

• Severe Uncontrolled Heart Conditions: Ozanimod should not be used by patients with severe, uncontrolled heart problems because of the possible cardiovascular hazards. These conditions include heart failure, severe or unstable angina, and some types of heart block.

Usage of Particular Medications: Ozanimod may interact with specific medications, especially those that reduce the heart rate or change cardiac rhythm (such as class I or III antiarrhythmic agents). This could make it dangerous to take these medications together.

• Severe Liver Impairment: Ozanimod should not be used in patients who have severe liver impairment (Child-Pugh Class C), as the medication may not be appropriate for them.

For Patients

Why Is Ozanimod Prescribed?

Ozanimod is primarily used to treat relapse types of multiple sclerosis (MS), though it is prescribed for the treatment of other autoimmune disorders as well. The main purpose for prescribing Ozanimod are as follows:

• Relapsing-Remitting Multiple Sclerosis (RRMS): Patients with RRMS (relapsing-remitting multiple sclerosis) are typically taken Ozanimod. Periods of symptom worsening (relapses) interspersed with remissions are the hallmarks of RRMS. Ozanimod is used to help people with RRMS experience fewer relapses, a slower rate of disability progression, and fewer new or increasing brain lesions.

• Active Secondary Progressive Multiple Sclerosis (SPMS): In patients with active secondary progressive multiple sclerosis (SPMS), where relapses and disease activity are still evident, Ozanimod is also recommended. It can help control the symptoms and delay the disease's advancement for these people.

What Precautions Are to Be Taken While Using Ozanimod?

It is crucial to follow certain guidelines when using Ozanimod to guarantee a secure and efficient course of treatment. The following are some safety measures to consider:

• Cardiovascular Health Monitoring: Ozanimod may lower heart rate, resulting in symptoms of bradycardia (slow heart rate). Before beginning treatment, people should have an electrocardiogram (ECG) to assess heart function. It is also advised to check the heart rate regularly while receiving treatment. Individuals who use drugs that alter heart rate or have a history of specific cardiac disorders need to be properly watched.

• Monitoring of Liver Function: Ozanimod may have an impact on liver function. It is important to conduct routine liver function testing, particularly in the first half-year of medication. Patients who already have a liver illness or whose liver function is abnormal need closer observation.

• Blood Pressure Monitoring: Ozanimod may result in hypertension (high blood pressure). Before the therapy, blood pressure should be measured, and it should be periodically evaluated while in treatment. It is important to treat hypertension as needed.

• Immunizations: Before beginning Ozanimod, people should be fully immunized against varicella and other live vaccines, as the drug may raise their risk of infection. Generally speaking, live vaccinations are not advised while receiving Ozanimod therapy.

• Recent Infections: If a patient has recently recovered from or is currently experiencing an infection, they should not begin Ozanimod medication. It is best to start Ozanimod when any outstanding infections have been fully treated.

• Risk of Macular Edema: Macular edema, or swelling in the back of the eye, has been linked to Ozonimod and may result in visual impairments. People should notify their healthcare physician when they notice any changes in their vision.

• Interactions With Other Medications: Because Ozanimod may interact with other medications, potentially causing negative effects, patients should disclose to their healthcare provider all the medicines, vitamins, and herbal items they use.

• Pregnancy and Contraception: Women of reproductive potential should use effective contraception during treatment and for three months after terminating Ozanimod due to the possibility that it may harm an unborn child. Talking about family planning with a healthcare professional is crucial.

• Breastfeeding: Because Ozanimod may pass into breast milk, women should refrain from breastfeeding while on treatment and for three days following the last dosage.

• Hypersensitivity Reactions: If a patient experiences a significant hypersensitivity reaction, therapy should be stopped, and they should keep an eye out for any indicators.

What Are Its Side Effects of Ozanimod?

Like any drug, Ozanimod may cause adverse reactions. These adverse effects vary in intensity and are not always felt by the same person. It is critical for Ozanimod users to be aware of any adverse effects and to notify the healthcare provider right away if there are any odd or severe symptoms. The following are a few typical Ozanimod side effects:

1. Headache: One of the more typical adverse effects is a headache.

2. Upper Respiratory Tract Infections: Common colds and other upper respiratory system infections may be more common.

3. Increased Liver Enzymes: Ozanimod has the potential to impact liver function and cause raised liver enzyme levels. Routine liver function tests are usually carried out to keep an eye on this.

4. Hypertension, or High Blood Pressure: Taking Ozanimod may cause an increase in blood pressure in certain people. Regular blood pressure monitoring is necessary.

5. Bradycardia (Decreased Heart Rate): Ozanimod can potentially induce bradycardia by lowering heart rate. Cardiac rate monitoring is crucial, particularly for people with cardiac issues.

6. Elevated Liver Function Tests: A rise in liver function tests may be observed in certain patients, suggesting possible liver problems.

7. Herpes Zoster (Shingles): People taking Ozanimod should be closely watched for symptoms as it may raise the chance of a reactivation of shingles.

8. Macular Edema: Some individuals have reported experiencing swelling in the eye's macula, known as macular edema, which can cause vision issues.

9. Raised Infection Risk: Ozanimod raises the risk of a number of infections, such as urinary tract and lung infections. Patients should be on the lookout for infection symptoms and notify the healthcare practitioner of any issues they experience.

10. Inflammatory Bowel Disease: Patients on Ozanimod have been documented to experience cases of inflammatory bowel disease (chronic inflammation of tissues in digestive symptoms).

11. Lung Infections: A higher risk of lung infections may be experienced by certain individuals.

12. Neutropenia: Ozanimod may infrequently result in a reduction in neutrophil counts, raising the possibility of infections.

13. Depressed Mood: A tiny percentage of patients have been reported to have experienced mood changes, including depression and suicidal thoughts.

For Doctors:

What Are the Considerations for Dose Alterations of Ozanimod?

Ozanimod dosage adjustments should only be made based on each patient's unique medical needs and how they respond to the drug. When adjusting the dosage of Ozanimod, keep the following points in mind:

• Starting Dose: To assist in lowering the likelihood of certain adverse effects, a recommended titration schedule spread out over several days is the standard starting dose of Ozanimod for treating multiple sclerosis. It is imperative to adhere to the prescribed titration plan as directed by the healthcare provider.

• Maintenance Dose: Patients usually attain the Ozanimod maintenance dose following the first titration phase. This is the dosage at which the patient's illness is effectively controlled.

• Response to Treatment: Depending on how the patient responds to treatment, dose adjustments may be considered. The healthcare practitioner may change the dosage if the patient has a noticeable rise in adverse effects or a noticeable decrease in disease activity.

• Adverse Reactions: Should the patient have negative reactions to Ozanimod, the physician may think about lowering the dosage or stopping the medication for a while. For instance, a dose modification or stoppage may be required if the patient experiences severe bradycardia or macular edema.

• Monitoring: While using Ozanimod, it is important to regularly check the patient's health, including blood pressure, liver function, and heart rate. Dosage adjustments can be required if any anomalies are found during monitoring.

• Special Populations: Because Ozanimod is processed in the liver, dose adjustments might be necessary for specific populations, such as those who have liver impairment. In these situations, the medical professional could modify the dosage by the patient's liver function.

• Drug Interactions: Ozanimod may interact with some drugs, requiring dose modifications. Patients should ensure the healthcare provider knows all the medications and supplements they use.

• Pregnancy and Contraception: Dosage adjustments may be necessary if a patient becomes pregnant or intends to become pregnant. Effective contraception should be used both during therapy and for a while after finishing the medicine, as Ozanimod is not advised during pregnancy.

• Discontinuation: Changing the dosage may also entail stopping the drug, particularly if there are serious side effects or it is not working as intended. The suitable protocol for cessation will be decided by the healthcare provider.

Pharmacokinetics of Ozanimod:

Ozanimod's pharmacokinetics studies the drug's absorption, distribution, metabolism, and excretion in the human body. An outline of Ozanimod's pharmacokinetics is shown below:

• Absorption: The oral administration of Ozanimod takes the shape of a tablet. The gastrointestinal tract absorbs it quickly, reaching peak plasma concentrations four to six hours after dosage. Food may influence the rate and degree of absorption, so taking Ozanimod regularly with or without food is advised.

• Distribution: Ozanimod has a wide distribution, with spots all over the body. The medication binds significantly to albumin and other plasma proteins.

• Metabolism: Ozanimod's metabolism occurs mostly in the liver, where the enzymes metabolize cytochrome P450 (CYP). Pharmacologically inactive CC112273 is the principal metabolite of Ozanimod. CYP4F2 is the main enzyme that is involved in its metabolism.

• Elimination: Hepatic metabolism plays a major role in removing Ozanimod and its metabolites. Just a tiny portion (about five percent) of the dose is eliminated in urine; the majority (approximately 81 percent) is eliminated in feces, mostly as metabolites.

• Half-Life: Ozanimod has a half-life of between 21 and 29 hours, which means it stays in the body longer.

• Steady-State: The concentrations attain a steady state after taking Ozanimod regularly for one to two weeks.

• Pharmacokinetic Variability: Age, gender, genetics, liver function, and concurrent pharmaceutical use can all impact the inter-individual variability in Ozanimod's pharmacokinetics.

• Dose Adjustments: Because the medication is processed in the liver, dose modifications can be required in some groups, such as those with hepatic impairment. Based on the needs and medical history of the patient, the dosage should be customized.

• Drug Interactions: Interactions with other drugs may impact Ozanimod's pharmacokinetics. Caution should be exercised when taking Ozanimod alongside medications processed by the same CYP enzymes.

Pharmacodynamics of Ozanimod

Understanding how Ozanimod affects the body at the molecular, cellular, and systemic levels is known as pharmacodynamics. Ozanimod mainly affects the immune system by modulating the sphingosine-1-phosphate (S1P) receptor. The following are the main pharmacodynamic features of Ozanimod:

• Modulation of S1P Receptors: Ozanimod is a selective modulator of some S1P receptors present on immune cells, specifically S1P1 and S1P5 receptors. It stops some immune cells, particularly lymphocytes, from leaving lymph nodes and entering the bloodstream by attaching to these receptors.

• Immune System Modulation: The immune system is modulated, which is the main pharmacodynamic impact of Ozanimod. It decreases the bloodstream's circulation of particular immune cells, mostly lymphocytes. Ozanimod reduces the amount of immune cells that can move into the central nervous system by keeping these cells in the lymph nodes. This lowers the inflammatory activity and autoimmune response in diseases like multiple sclerosis.

• Decrease in Inflammatory Attacks: In multiple sclerosis, inflammation, and demyelination result from the immune system attacking the central nervous system. The pharmacodynamic impact of Ozanimod aids in limiting the quantity of immune cells that can infiltrate the central nervous system. As a result, the frequency of inflammatory episodes, relapses, and related symptoms declines.

• Effects on Heart Rate: Ozanimod may impact heart rate in a secondary pharmacodynamic manner. Bradycardia, a drop in heart rate, could result from it. The S1P receptor binding on cardiac cells brings on this lower heart rate. Cardiac rate monitoring is crucial when using Ozanimod, particularly for those with cardiac issues.

• Decrease in New Brain Lesions: Patients with multiple sclerosis see a decrease in the number of new or expanding brain lesions due to Ozonimod's effect on immune cell migration into the central nervous system.

Ozanimod Toxicity

When administered by prescribed therapeutic dosages, Ozanimod is typically well tolerated. But if overused or misused, it can have hazardous effects like any other medication. To reduce the risk of toxicity, patients must strictly adhere to the recommended dosage and treatment plan as well as the recommendations from their healthcare professional. Some things to think about regarding Ozanimod toxicity are as follows:

• Overdose: If one takes more Ozanimod than is recommended, they run the risk of experiencing serious side effects, such as bradycardia or a sluggish heartbeat. An overdose should be quickly reported to a healthcare professional, and the patient should seek the necessary medical attention.

• Abnormal Heart Rhythms: Ozanimod may cause bradycardia, which may be hazardous if severe. When taking Ozanimod, patients with pre-existing cardiac issues may be more susceptible to irregularities in their heart rhythm.

• Macular Edema: Ozanimod has occasionally been linked to macular edema or swelling in the eye's macula. This needs to be watched because it may impair vision. Severe instances can be regarded as poisonous.

• Hypersensitivity Reactions: Rarely, hypersensitivity reactions might happen. These reactions can look like rashes, itching, or hives. Severe hypersensitivity reactions need to be recorded since they may be hazardous reactions.

• Other Adverse Effects: Although not always a sign of toxicity, other Ozanimod side effects should be properly watched since they might need to be treated differently. A few examples are headaches, elevated blood pressure, upper respiratory tract infections, and alterations in hepatic function.